Sales at French health care and beauty products company Sanofi rose 8% in the first nine months of 1994 to 18.18 billion French francs ($3.53 billion), with the human health care sector rising 8.0% to 9.92 billion francs, Bio-activities up 46.9% to 3.07 billion francs and perfumes and beauty products falling 4.6% to 5.19 billion francs. The pharmaceutical business registered good growth in Northern European markets, and sales growth remained high in developing trading areas, notably Asia and Central Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze